Published in Dermatol Ther (Heidelb) on January 23, 2014
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3) | NCT01646177
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1) | NCT01474512
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today (2015) 0.79
Secukinumab. Hosp Pharm (2015) 0.75
Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm (2015) 0.75
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Indian J Dermatol (2017) 0.75
Hypomorphic A20 expression confers susceptibility to psoriasis. PLoS One (2017) 0.75
Psoriasis. N Engl J Med (2009) 8.80
Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis (2004) 6.54
Structure and signalling in the IL-17 receptor family. Nat Rev Immunol (2009) 6.38
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 6.19
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med (2012) 6.01
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol (2003) 4.45
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem (2003) 3.41
Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun (2005) 2.66
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol (2007) 2.40
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol (2010) 1.66
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol (2013) 1.60
Which are the antibodies to watch in 2013? MAbs (2012) 1.56
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol (2013) 1.50
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol (2013) 1.46
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol (2007) 1.41
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis (2007) 1.37
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Psoriasis: rationale for targeting interleukin-17. Br J Dermatol (2012) 1.14
TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol (2011) 1.10
Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol (2013) 1.10
Emerging role of IL-17 in atherosclerosis. J Innate Immun (2010) 0.99
IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs (2013) 0.98
Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol (2013) 0.90
Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol (2012) 0.87
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol (2012) 0.87
Latitude and psoriasis prevalence. J Am Acad Dermatol (2011) 0.79
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol (2007) 2.17
Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol (2014) 2.13
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs (2014) 1.99
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol (2006) 1.77
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol (2003) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges (2010) 1.60
Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol (2005) 1.54
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol (2003) 1.43
Annular lichenoid dermatitis of youth. J Am Acad Dermatol (2003) 1.40
Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol (2006) 1.40
Subcutaneous sarcoidosis: report of two cases and review of the literature. Clin Rheumatol (2011) 1.29
Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol (2007) 1.26
Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24
ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol (2005) 1.23
The role of chemokines in allergic contact dermatitis. Arch Dermatol Res (2002) 1.22
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr (2008) 1.21
Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost (2009) 1.21
Drug-induced lupus erythematosus. Arch Dermatol Res (2008) 1.16
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 1.15
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol (2009) 1.09
STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J (2010) 1.09
Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol (2010) 1.09
Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol (2003) 1.09
Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood (2002) 1.08
Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy (2005) 1.08
Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology (2008) 1.06
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol (2005) 1.03
The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) (2012) 1.02
Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol (2002) 1.00
Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release. J Cell Physiol (2004) 0.99
Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol (2010) 0.99
Chemokine networks in inflammatory skin diseases. Eur J Dermatol (2004) 0.98
Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol (2009) 0.98
Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg (2012) 0.97
The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol (2006) 0.97
Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol (2010) 0.96
H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol (2004) 0.96
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol (2008) 0.96
Mid-dermal elastolysis: a clinical, histologic, and immunohistochemical study of 11 patients. J Am Acad Dermatol (2003) 0.95
Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol (2002) 0.95
Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol (2002) 0.95
Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol (2016) 0.93
Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol (2010) 0.93
Endometriosis of umbilical cicatrix: case report and review of the literature. Acta Dermatovenerol Croat (2008) 0.92
Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. J Invest Dermatol (2006) 0.92
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. Hum Hered (2006) 0.91
Activin A induces Langerhans cell differentiation in vitro and in human skin explants. PLoS One (2008) 0.91
Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets (2008) 0.91
Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J Immunol (2002) 0.91
Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat (2010) 0.91
Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol (2008) 0.91
Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges (2012) 0.89
The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study. J Nephrol (2009) 0.89
Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity (2010) 0.89
Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am J Pathol (2002) 0.88
Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol (2010) 0.87
The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol (2002) 0.87
Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol (2004) 0.87
Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Res Technol (2009) 0.87
Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol (2014) 0.87
The diagnostic and therapeutic challenge of early psoriatic arthritis. Dermatology (2010) 0.87
Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol (2011) 0.86
Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol (2010) 0.86
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol (2016) 0.85
Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist (2011) 0.85
Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract (2005) 0.84
Multiple self-healing squamous epithelioma in different ethnic groups: more than a founder mutation disorder? J Invest Dermatol (2007) 0.84
Contact allergy in chronic eczematous lip dermatitis. Eur J Dermatol (2008) 0.84
Nickel-specific CD4(+) and CD8(+) T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol (2002) 0.84
Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev (2007) 0.84
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther (2010) 0.84
Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res (2003) 0.83
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res (2012) 0.83
Buschke-Ollendorff syndrome. Int J Dermatol (2008) 0.83
Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology (2014) 0.83
Psoriasis and risk of myocardial infarction. JAMA (2007) 0.83
Videocapillaroscopy in the differential diagnosis between psoriasis and seborrheic dermatitis of the scalp. Dermatology (2007) 0.82
Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy (2004) 0.82
Folic acid in general medicine and dermatology. J Dermatolog Treat (2007) 0.82
Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res (2013) 0.82
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol (2006) 0.81
Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol (2005) 0.81
Predictive model for delayed graft function based on easily available pre-renal transplant variables. Intern Emerg Med (2014) 0.81
Efficacy of a single educative intervention in patients with chronic plaque psoriasis. Dermatology (2009) 0.81
Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. J Am Acad Dermatol (2010) 0.81
Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther (2010) 0.81
Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema. Dermatol Ther (2008) 0.81
Activation of nickel-specific CD4+ T lymphocytes in the absence of professional antigen-presenting cells. J Invest Dermatol (2002) 0.80
Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germline R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor. Future Oncol (2014) 0.80
House dust mite allergen exerts no direct proinflammatory effects on human keratinocytes. J Allergy Clin Immunol (2002) 0.80
Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. Dermatology (2012) 0.80
Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis? J Eur Acad Dermatol Venereol (2012) 0.80
Purely follicular mycosis fungoides without mucinosis: report of two cases with review of the literature. J Am Acad Dermatol (2003) 0.79
Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol (2006) 0.79